11 Comments
User's avatar
David Pare's avatar

Here's a suggested modification to the strategy - to avoid the dramatic drawdowns during recessions. (for informational purposes only).

There are a handful of indicators that spike higher right before recessions start. My current favorite: UNRATE. When it jumps higher, perhaps - move into a "50% cash" position when you see this happen. The rest of the time you just do your usual thing.

JEFFREY BARFIELD's avatar

STEVE THANK YOU FOR BEING SO INVENTIVE IN FINDING NEW WAYS TO PROVE A POINT. WELL ABOVE BIG PHARMAS CAPERBILITIES. ALL THEY DO IS FIDDLE THE FIGURES AND EARN $BILLIONS IN DOING SO. ALSO COVERUPS INCLUDED.

Joy N.'s avatar

🙏🙏

What the Holy Bible says of this horrific decade just ahead of us.. Here's a site expounding current global events in the light of bible prophecy.. To understand more, pls visit 👇 https://bibleprophecyinaction.blogspot.com/

buddhi's avatar

Record levels of corporate buybacks, potentially hitting $1 trillion in 2025, are artificially inflating prices without underlying business growth.

Andrew's avatar

That's the paradigm shift we need to make if we have a chance in hell, instead of investing just to make money we need to get back to being involved in what we are investing in.

I can make money off war, which we are rapidly heading into, but that's not the future I want to participate in.

Steve, you are basically doing what the Big Pharma boys are doing by thinking it's all about the money.

buddhi's avatar

Not bad. (Why does it work?) Better chain your computer to the floor.

buddhi's avatar

Fundamentals have been beaten to death - I don't think it's fundamentals unless you really stretch the definition. (I see how you did it - just need to think different, in reverse - I ain't gonna tell)

Lori's avatar

Steve, have you seen the new study about covid jabs and cancer that big harma is having apoplexy over and trying to bury all over the internet? Here is info and abstract.

Oncotarget, 2026, Vol. 17, pp: 1-29

COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms Charlotte Kuperwasser1,2 and Wafik S. El-Deiry3,4,5 1 Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111, USA 2 Laboratory for the Convergence of Biomedical, Physical, and Engineering Sciences, Tufts University School of Medicine, Boston, MA 02111, USA 3 Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 029121, USA 4 Hematology-Oncology Division, Department of Medicine, Brown University Health and The Warren Alpert Medical School of Brown University, Providence, RI 029121, USA 5 Legorreta Cancer Center at Brown University, The Warren Alpert Medical School of Brown University, Providence, RI 029121, USA Correspondence to: Charlotte Kuperwasser, email: charlotte.kuperwasser@tufts.edu Wafik S. El-Deiry, email: wafik@brown.edu Keywords: COVID; vaccine; cancer; infection; lymphoma; leukemia; sarcoma; carcinoma Received: November 26, 2025 Accepted: December 26, 2025 Published: January 03, 2026 Copyright: © 2026 Kuperwasser and El-Deiry. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT A growing number of peer-reviewed publications have reported diverse cancer types appearing in temporal association with COVID-19 vaccination or infection. To characterize the nature and scope of these reports, a systematic literature search from January 2020 to October 2025 was conducted based on specified eligibility criteria. A total of 69 publications met inclusion criteria: 66 article-level reports describing 333 patients across 27 countries, 2 retrospective population-level investigations (Italy: ~300,000 cohort, and Korea: ~8.4 million cohort) quantified cancer incidence and mortality trends among vaccinated populations, and one longitudinal analysis of ~1.3 million US miliary service members spanning the pre-pandemic through postpandemic periods. Most of the studies documented hematologic malignancies (nonHodgkin’s lymphomas, cutaneous lymphomas, leukemias), solid tumors (breast, lung, melanoma, sarcoma, pancreatic cancer, and glioblastoma), and virus-associated cancers (Kaposi and Merkel cell carcinoma). Across reports, several recurrent themes emerged: (1) unusually rapid progression, recurrence, or reactivation of preexisting indolent or controlled disease, (2) atypical or localized histopathologic findings, including involvement of vaccine injection sites or regional lymph nodes, and (3) proposed immunologic links between acute infection or vaccination and tumor dormancy, immune escape, or microenvironmental shifts. The predominance of caselevel observations and early population-level data demonstrates an early phase of potential safety-signal detection. These findings underscore the need for rigorous epidemiologic, longitudinal, clinical, histopathological, forensic, and mechanistic studies to assess whether and under what conditions COVID-19 vaccination or infection may be linked with cancer.

Steve Kirsch's avatar

yes. not surprising